In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease

Elena Schartmann, Sarah Schemmert, Nicole Niemietz, Dominik Honold, Tamar Ziehm, Markus Tusche, Anne Elfgen, Ian Gering, Oleksandr Brener, N. Jon Shah, Karl‐Josef Langen, Janine Kutzsche, Dieter Willbold, Antje WilluweitJournal of Alzheimer s Disease 2018 · DOI

TL;DR

This study investigates three D-enantiomeric peptides (ANK6, tANK6, and cANK6r) as potential treatments for Alzheimer's Disease (AD). All three peptides demonstrated strong in vitro efficacy in inhibiting Aβ aggregation, clearing Aβ oligomers, and reducing Aβ-induced cell toxicity. Preclinical studies in mice showed promising blood-brain barrier penetration, with the cyclized peptide (cANK6r) achieving the highest brain concentrations, making these peptides strong candidates for further AD drug development.

What Problem Does This Paper Address?

Alzheimer's Disease (AD) is a devastating neurodegenerative disorder characterized by the accumulation of amyloid-beta (Aβ) plaques and tau tangles in the brain. While Aβ plaques have long been a focus, current research increasingly points to soluble Aβ oligomers as the primary culprits driving AD pathogenesis and neurotoxicity. Developing effective therapeutic agents that can target and neutralize these toxic oligomers is a critical unmet need. Previous work by the authors identified D3, a D-enantiomeric peptide, and its derivatives as promising candidates. This paper aims to further optimize these D-peptides by comparing ANK6, a promising derivative, with two modified versions: tANK6 (a tandem repeat) and cANK6r (a head-to-tail cyclized form). The goal is to assess their in vitro potency and, crucially, their preclinical pharmacokinetic profiles, particularly their ability to cross the blood-brain barrier (BBB), to identify the most viable candidates for AD treatment.

Methods

The researchers employed a multi-pronged approach to evaluate the D-peptides:

  • In Vitro Potency Assays:
    • Aβ Aggregation Assay (Thioflavin T): This standard method measures the ability of the peptides to inhibit the formation of Aβ fibrils, a key step in plaque formation.
  • Aβ Oligomer Elimination Assay (QIAD): This assay quantifies the peptides' effectiveness in removing pre-formed Aβ oligomers from a solution by analyzing aggregate size distribution.
  • Cell Viability Assay (MTT): This assay assesses the peptides' ability to protect neuronal cells (PC12 cells) from the toxic effects of Aβ oligomers.
  • Preclinical Pharmacokinetic Studies:
    • Plasma Protein Binding (PPB): The binding affinity of the peptides to major human plasma proteins (HSA and AGP) was determined to understand their distribution and potential for sustained release.
  • In Vivo Pharmacokinetics: The peptides were administered intravenously (i.v.) and orally (p.o.) to C57BL/6N mice. Blood, brain, liver, kidney, and cerebrospinal fluid (CSF) samples were collected at various time points to measure peptide concentrations. This allowed for the determination of key pharmacokinetic parameters like Cmax, AUC, half-life, and oral bioavailability.
  • Blood-Brain Barrier (BBB) Permeability: Specific BBB parameters (logBB, Kin, Vi, PS) were calculated to quantitatively assess the peptides' ability to cross the BBB.

Datasets

Not discussed in the paper. The study utilized synthesized peptides and commercially available Aβ1-42.

Key Insights and Ideas

  • Tandem and Cyclic Modifications Enhance Efficacy: Both the tandem (tANK6) and cyclized (cANK6r) versions of ANK6 showed improved or comparable in vitro potency compared to the parent ANK6 and the original lead compound D3. This highlights the effectiveness of these structural modifications in optimizing Aβ targeting.
  • Oligomer Clearance is Key: The QIAD assay revealed that all three peptides were highly effective at eliminating Aβ oligomers, a crucial mechanism for mitigating AD pathology.
  • BBB Penetration is Promising, Especially for cANK6r: The pharmacokinetic studies demonstrated that these D-peptides can cross the BBB. Notably, the cyclized peptide (cANK6r) achieved the highest brain concentrations, suggesting that cyclization is a successful strategy for enhancing brain delivery.
  • Oral Administration is Viable: The study showed that oral administration of these peptides resulted in significant systemic exposure and brain penetration, which is highly desirable for a long-term therapeutic.
  • Plasma Protein Binding Offers Potential for Sustained Release: The peptides showed strong binding to AGP, suggesting they could act as drug reservoirs, leading to sustained drug levels and potentially allowing for less frequent dosing.

Key Results

  • In Vitro Potency:
    • Aβ Aggregation Inhibition: IC50 values were 3.6 µM (ANK6), 2.1 µM (tANK6), 3.7 µM (cANK6r), and 7.2 µM (D3). tANK6 was the most potent inhibitor.
  • Aβ Oligomer Elimination (QIAD): ANK6, tANK6, and cANK6r significantly lowered Aβ oligomer concentrations in critical fractions (4-6) compared to the control.
  • Cell Viability: At a 1:5 Aβ:peptide ratio, ANK6, tANK6, and cANK6r maintained cell viability at 65.3%, 75.5%, and 58%, respectively. IC50 values for reducing Aβ-induced cytotoxicity were 11 µM (ANK6), 4.4 µM (tANK6), and 14 µM (cANK6r).
  • Pharmacokinetics (Key Highlights):
    • Brain Exposure: cANK6r showed the highest brain AUC after i.v. administration, while tANK6 had the highest brain AUC after oral administration.
  • Brain/Plasma Ratio: Ratios were generally favorable, indicating good brain uptake relative to plasma levels.
  • Oral Bioavailability: tANK6 exhibited a notably high oral bioavailability (49.4%), while ANK6 (11.8%) and cANK6r (9.9%) were also significant.
  • BBB Permeability: Calculated BBB parameters indicated efficient penetration for all three peptides, with tANK6 showing particularly high Kin and PS values.

Limitations and Future Work

  • Limitations:
    • The study acknowledges that the tritium labeling of peptides, while generally stable, might not perfectly represent the behavior of unmodified compounds, introducing a minor uncertainty.
  • While the in vitro results are promising, the in vivo efficacy in animal models of AD was not directly tested in this specific study, though previous work with D3 and its derivatives has shown positive outcomes.
  • The study used wild-type mice, and future studies would benefit from testing in transgenic AD models to assess efficacy in a disease context.
  • Future Work:
    • The authors suggest that the promising in vitro and preclinical pharmacokinetic data warrant further investigation in therapeutic studies, particularly in transgenic AD mouse models.
  • The development of tandem and cyclized peptides offers a clear path for further optimization of Aβ-targeting D-peptides for AD treatment.
  • The high oral bioavailability and BBB penetration of these peptides make them excellent candidates for long-term oral AD therapy.

Summary updated

Abstract

Diffusible amyloid-β (Aβ) oligomers are currently presumed to be the most cytotoxic Aβ assembly and held responsible to trigger the pathogenesis of Alzheimer's disease (AD). Thus, Aβ oligomers are a prominent target in AD drug development. Previously, we reported on our solely D-enantiomeric peptide D3 and its derivatives as AD drug candidates. Here, we compare one of the most promising D3 derivatives, ANK6, with its tandem version (tANK6), and its head-to-tail cyclized isoform (cANK6r). In vitro tests investigating the D-peptides' potencies to inhibit Aβ aggregation, eliminate Aβ oligomers, and reduce Aβ-induced cytotoxicity revealed that all three D-peptides efficiently target Aβ. Subsequent preclinical pharmacokinetic studies of the three all-D-peptides in wildtype mice showed promising blood-brain barrier permeability with cANK6r yielding the highest levels in brain. The peptides' potencies to lower Aβ toxicity and their remarkable brain/plasma ratios make them promising AD drug candidates.
BibTeX
@article{schartmann2018vitro,
  author = {Elena Schartmann and Sarah Schemmert and Nicole Niemietz and Dominik Honold and Tamar Ziehm and Markus Tusche and Anne Elfgen and Ian Gering and Oleksandr Brener and N. Jon Shah and Karl‐Josef Langen and Janine Kutzsche and Dieter Willbold and Antje Willuweit},
  title = {{In Vitro Potency and Preclinical Pharmacokinetic Comparison of All-D-Enantiomeric Peptides Developed for the Treatment of Alzheimer’s Disease}},
  journal = {Journal of Alzheimer s Disease},
  year = {2018},
  doi = {10.3233/jad-180165},
}
Figure